NDAORALTABLET
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
COMBOGESIC (acetaminophen and ibuprofen) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for minor aches, pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis. First approved in 2023.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC is a fixed-dose combination tablet of acetaminophen and ibuprofen approved by the FDA in March 2023. It treats minor aches and pains including headaches, toothaches, backaches, menstrual cramps, and arthritis-related pain through dual cyclooxygenase inhibition. The combination leverages complementary analgesic and anti-inflammatory mechanisms to provide enhanced pain relief in a single oral formulation.
Peak12.3 years to LOE
Product is at peak commercial maturity with strong patent protection; brand team is likely stable or moderately sized, focused on market penetration and line extension strategies.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on COMBOGESIC at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.